| scholarly article | Q13442814 |
| P50 | author | Paul Quax | Q40233730 |
| P2093 | author name string | Andreas G Niethammer | |
| Ralph A Reisfeld | |||
| Vincent van Weel | |||
| Johan Kuiper | |||
| Erik A L Biessen | |||
| Theo J C van Berkel | |||
| Eva J A van Wanrooij | |||
| Paula de Vos | |||
| Gijs H M van Puijvelde | |||
| Niels Peterse | |||
| Arnaud D Hauer | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 2050-2057 | |
| P577 | publication date | 2007-06-28 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis | |
| P478 | volume | 27 |
| Q27302261 | A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice |
| Q38073528 | A perspective for atherosclerosis vaccination: is there a place for plant-based vaccines? |
| Q40119196 | A vaccine against atherosclerosis: myth or reality? |
| Q37709623 | Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases |
| Q37645436 | Angiogenesis in the atherosclerotic plaque. |
| Q38293518 | Antisense oligonucleotides, microRNAs, and antibodies. |
| Q50100038 | Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. |
| Q38137846 | Can we vaccinate against atherosclerosis? |
| Q37696318 | Combining nanotechnology with current biomedical knowledge for the vascular imaging and treatment of atherosclerosis |
| Q52691045 | DEC205-DC targeted DNA vaccine against CX3CR1 protects against atherogenesis in mice. |
| Q35738533 | DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration. |
| Q43179678 | Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices |
| Q57162894 | Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology |
| Q37828065 | Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. |
| Q53286737 | IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice. |
| Q24313566 | Identification of protein kinase D2 as a pivotal regulator of endothelial cell proliferation, migration, and angiogenesis |
| Q91404901 | Induction of HLA-A2 restricted CD8 T cell responses against ApoB100 peptides does not affect atherosclerosis in a humanized mouse model |
| Q38826454 | Intraplaque neovascularization as a novel therapeutic target in advanced atherosclerosis |
| Q52640510 | Live Bacterial Vectors-A Promising DNA Vaccine Delivery System. |
| Q36000386 | Microfluidic endothelial cell culture model to replicate disturbed flow conditions seen in atherosclerosis susceptible regions |
| Q38125279 | Molecular biology of atherosclerosis |
| Q30974890 | Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study |
| Q58599881 | PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis |
| Q38422308 | Potential contributions of intimal and plaque hypoxia to atherosclerosis |
| Q37960607 | Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors |
| Q57821678 | Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis |
| Q33681553 | Redox regulation of ischemic limb neovascularization - What we have learned from animal studies |
| Q33663533 | Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study |
| Q38593722 | The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials |
| Q46470925 | Therapeutic strategies for endothelial dysfunction |
| Q37530710 | Vaccination for atherosclerosis |
| Q43251127 | Vaccination, atherosclerosis and systemic lupus erythematosus |
| Q33641227 | Vaccine against arteriosclerosis: an update |
| Q54176935 | Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells. |
Search more.